Outcomes in Critically Ill Allogeneic Hematopoietic Stem-Cell Transplantation Recipients

Antoine Lafarge1, Thibault Dupont1, Emmanuel Canet2

  • 1Service de Médecine Intensive et Réanimation and.

Insights

Critically ill allogeneic hematopoietic stem-cell transplantation (Allo-HSCT) patients admitted to the ICU have a 90-day survival rate of 51.8%. Age, graft-versus-host disease, and need for vasopressors or mechanical ventilation are key mortality predictors.

Area of Science:

  • Critical Care Medicine
  • Hematology
  • Transplantation Immunology

Background:

  • Allogeneic hematopoietic stem-cell transplantation (Allo-HSCT) recipients are often considered poor candidates for intensive care unit (ICU) management.
  • This perception necessitates a closer examination of outcomes and mortality predictors in this vulnerable patient population.

Purpose of the Study:

  • To investigate the outcomes and identify determinants of mortality in critically ill Allo-HSCT patients admitted to the ICU.
  • To evaluate the 90-day mortality rate and associated risk factors in this cohort.

Main Methods:

  • A large, multicenter retrospective cohort study involving 1,164 Allo-HSCT patients admitted to 14 French ICUs between January 1, 2015, and December 31, 2020.
  • Data collection included patient demographics, clinical status at ICU admission, interventions received (mechanical ventilation, renal replacement therapy, vasopressors), and mortality outcomes.

Main Results:

  • The overall ICU mortality was 26%, with 90-day, 1-year, and 3-year mortality rates of 48%, 63%, and 70%, respectively.
  • Key independent predictors of 90-day mortality included older age (>56 years), time from Allo-HSCT to ICU admission (30-90 days), corticosteroid-refractory acute graft-versus-host disease, and need for vasopressors or mechanical ventilation.
  • In patients requiring mechanical ventilation, mortality ranged from 39% to 100% based on the number of associated risk factors.

Conclusions:

  • The majority of critically ill Allo-HSCT recipients, including those requiring mechanical ventilation, survive ICU stays, with a 90-day survival rate of 51.8%.
  • A thorough assessment of goals of care is crucial for patients with two or more identified risk factors for mortality.

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
321
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
354
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K